# A Study of CBX-250 in Participants With Relapsed or Refractory Myeloid Leukemias

> **NCT06994676** · PHASE1 · RECRUITING · sponsor: **Crossbow Therapeutics, Inc.** · enrollment: 72 (estimated)

## Conditions studied

- High-risk Myelodysplastic Syndrome
- Chronic Myelomonocytic Leukemia (CMML)
- AML - Acute Myeloid Leukemia
- Chronic Myeloid Leukemia

## Interventions

- **DRUG:** CBX-250

## Key facts

- **NCT ID:** NCT06994676
- **Lead sponsor:** Crossbow Therapeutics, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-07-16
- **Primary completion:** 2027-01
- **Final completion:** 2027-06
- **Target enrollment:** 72 (ESTIMATED)
- **Last updated:** 2026-03-16


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06994676

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06994676, "A Study of CBX-250 in Participants With Relapsed or Refractory Myeloid Leukemias". Retrieved via AI Analytics 2026-06-04 from https://api.ai-analytics.org/clinical/NCT06994676. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*